In the inpatient setting, physicians face the cumbersome and time-consuming task of determining the most cost-effective anticoagulation medication for patients with newly discovered pulmonary embolism or deep vein thrombosis.
Become a Huddle+ member below for full access to a detailed problem description, root cause and impact analyses, and three solutions to the problem.
Become a paying subscriber of Huddle+ to get access to this post and other subscriber-only content.
Already a paying subscriber? Sign In.